Clinical Trial Update: Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED) [Phase 3]

View source ↗

Summary

This ClinicalTrials.gov entry reports on a Phase 3 study (NCT00521924) of additional infliximab therapy to induce remission in rheumatoid arthritis patients wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Rheumatoid Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2009-06-01